GlassScriptPhysician profile
Bianca C Monteiro
NPI 1467615013
$42,955.86
in general payments reported to CMS, 2019-2025
12 companies · $8,200 in 2025
The $8,200 reported for 2025 was more than what 92% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,345 · 2020: $138 · 2021: $4,086 · 2022: $5,309 · 2023: $8,129 · 2024: $11K · 2025: $8,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Education: $5,517 · Travel and Lodging: $3,714 · Food and Beverage: $1,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,295.00 |
| Education | $5,517.38 |
| Travel and Lodging | $3,714.31 |
| Food and Beverage | $1,551.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $34,120.50 | 2019-2024 | Uptravi, Opsumit |
| Intuitive Surgical, INC. | $7,794.00 | 2025 | |
| United Therapeutics Corporation | $240.58 | 2023-2024 | Remodulin, Orenitram, Steen Solution |
| Merck Sharp & Dohme LLC | $217.59 | 2023-2025 | Winrevair |
| Glaxosmithkline, LLC. | $194.01 | 2020-2022 | |
| Genzyme Corporation | $171.04 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $89.81 | 2021-2025 | Wainua |
| Biogen, INC. | $48.24 | 2025 | Tysabri, Vumerity |
| Pfizer INC. | $28.33 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $17.84 | 2025 | Austedo Xr |
| Insmed, INC. | $17.38 | 2025 | Brinsupri |
| Cala Health, INC. | $16.54 | 2025 | Cala Kiq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bianca Monteiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.